BBT-176, a novel agent designed to inhibit EGFR with C797S mutations, will start first-in-human studies in NSCLC this year.
Five Prime Therapeutics provided an update on the development of bemarituzumab and FPA150, and Gritstone Oncology discussed plans for its personalized immunotherapies.
The companies will develop tissue-based companion diagnostics for Amgen's investigational treatment AMG 510 for non-small cell lung cancer.
In NSCLC driven by MET exon 14 alterations, research indicates Xalkori had some activity.
The company plans to submit a companion diagnostic version of its sequencing-based liquid biopsy test Guardant360 to various regulatory bodies.
The company will submit the data as part of a new drug application for pralsetinib for RET fusion-positive non-small cell lung cancer.
The approval will allow clinicians to identify NSCLC patients with ROS1 fusion genes who could benefit from treatment with Rozlytrek.
Experimental EGFR inhibitor fell short of desired objective response rate in patients with non-small cell lung cancer.
The drug is designed to tackle C797S resistance mutations that arise in NSCLC patients after treatment with third-generation tyrosine kinase inhibitors.
The company is enrolling up to 400 patients in its LIBRETTO-431 trial to evaluate survival and response to selpercatinib.